<DOC>
	<DOCNO>NCT00308607</DOCNO>
	<brief_summary>The purpose study determine whether combination therapy bevacizumab ( Avastin ) , dacarbazine interferon-alfa-2a ( Roferon-A ) effective patient locally advance metastatic melanoma .</brief_summary>
	<brief_title>Bevacizumab , Dacarbazine Interferon-Alfa Treat Metastatic Melanoma</brief_title>
	<detailed_description>Dacarbazine ( DTIC ) approve treat metastatic melanoma 1970s , numerous schedule dacarbazine-based combination study disease . DTIC single agent give response rate 20 % , effort improve poor result use DTIC different combinations.Treatment melanoma combination chemotherapy interferon-α ( IFN-α ) give 50-60 % response rate , increase overall survival time reach controlled phase III study . Thus , standard reference therapy treatment metastatic melanoma still single dacarbazine combination s.c. IFN-α . In addition , new study melanoma cell vitro show dacarbazine cause transcriptional up-regulation vascular endothelial growth factor ( VEGF ) , suggest potential clinical benefit combination DTIC anti-VEGF therapy . IFN-α use adjuvant therapy treatment metastatic melanoma . IFN-α exerts effect antiproliferative , apoptosis-inducing particularly antiangiogenic effect addition immunologic modulation . The purpose study determine whether combination therapy bevacizumab ( Avastin ) , dacarbazine interferon-alfa-2a ( Roferon-A ) increase progression-free survival overall survival patient locally advance metastatic melanoma .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>histologically confirm malignant melanoma either locally progress inoperable metastatic measurable/evaluable disease accordance RECIST criterion WHO performance status 02 normal organ function sign write informed consent unevaluable disease major surgery within 28 day prior day 0 uncompleted radiotherapy CNS metastases serious nonhealing wound ulcer bleed diathesis coagulopathy uncontrolled hypertension clinically significant cardiovascular disease depression psychosis , need medication ongoing treatment aspirin ( &gt; 325 mg/day ) pregnancy serious uncontrolled illness previous chemotherapy metastatic melanoma</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2009</verification_date>
	<keyword>melanoma</keyword>
	<keyword>metastatic</keyword>
	<keyword>bevacizumab</keyword>
</DOC>